top of page

Developing Innovative Therapeutics

Our Company

Inflection Biosciences is developing small molecule therapeutics for the treatment of cancer, autoimmune and inflammatory disease. The pipeline comprises of IBL-202, selected from a series of unique dual mechanism kinase inhibitors and AUM302 (formerly IBL-302), partnered with AUM Biosciences.

What We Do

Pipeline

Partnerships

NEWS

Inflection Biosciences Announces Pre-Clinical Data for IBL-202 in Mature T-Cell Lymphoma Published in European Journal of Haematology

Dublin, Ireland, April 6 2025 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...

Inflection Biosciences

Apr 6

Inflection Biosciences Announces Pre-Clinical Data for IBL-202 in PTCL Presented at the Inaugural West German Lymphoma Symposium

Dublin, Ireland, June 4 2024 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...

Inflection Biosciences

Jun 4, 2024

Inflection Biosciences Announces Licensing of PIM kinase Inhibitors to Mysthera Therapeutics

Dublin, Ireland, August 21 2023 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...

Inflection Biosciences

Aug 21, 2023

bottom of page